Phase 1 First-in-Human Study of JNJ-95566692 in Participants with Non-Hodgkin Lymphoma

The primary objective of this Phase 1 study is to evaluate the safety and pharmacokinetics of JNJ-95566692 in individuals diagnosed with non-Hodgkin lymphoma. Establishing the initial safety profile and metabolic characteristics of this compound is critical for determining appropriate dosing parameters in this patient population. Trial scope legend: 4: Safety; 6: Pharmacokinetic.

This clinical trial involves a total of 71 patients diagnosed with non-Hodgkin lymphoma. The study population includes both males and females within the pediatric and adolescent age ranges. The sponsor did not provide specific information regarding lifestyle considerations or additional selection processes.

This is a Phase 1, first-in-human study designed to evaluate JNJ-95566692 in participants diagnosed with non-Hodgkin lymphoma. The research methodology involves a sequence of study visits beginning with a screening visit to determine eligibility. Following enrollment, participants will undergo scheduled follow-up visits and an end-of-study visit. The total duration of participant involvement is determined by the specific study protocols. Early termination from the study may occur based on predefined clinical conditions or safety criteria.

The assessment of efficacy in this phase 1 clinical trial regarding Non-Hodgkin Lymphoma is not specified.